Investing
BioMarin Pharma gains on report Elliott has a stake
© Reuters. BioMarin Pharma (BMRN) gains on report Elliott has a stake
Activist investor Elliott Investment Management has acquired a stake in BioMarin Pharmaceutical (NASDAQ:), according to Reuters.
The hedge fund has engaged in discussions with the biotechnology company regarding its future. Elliott, which is overseeing approximately $60 billion in assets, invested over $1 billion in BioMarin, the report added.
BioMarin’s market cap stood at $14.34 billion through Monday’s close.
BioMarin’s shares have seen a 24% decline year-to-date, significantly underperforming the iShares Biotechnology ETF, which has a decrease of 8.6%. Shares added 9.5 in early Tuesday trade on Reuters’ reporting.
Elliott has previously targeted healthcare companies like Catalent (NYSE:), where it secured board seats in August, and Syneos, participating in a consortium that privatized the company this year.
The activist investor has also been successful in advocating for the sale of pharmaceutical companies like Alexion (NASDAQ:) Pharma and Allergan (NYSE:).
Read the full article here
-
Passive Income7 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles6 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles7 days ago
How Your Body Language Can Help Win a Disagreement
-
Investing7 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Investing5 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles7 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles6 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool
-
Side Hustles5 days ago
Mark Zuckerberg Is Now Second Richest Person in the World